• About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services
  • About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services

Philochem to attend as Lecturer to the Summer School in Pharmaceutical Analysis 2024 in Rimini on September 18-20, 2024

by Lisa Nadal | May 24, 2024 | Past Events

Dr. Ettore Gilardoni (Head of Mass Spectrometry) will participate as Lecturer to the Summer School in Pharmaceutical Analysis 2024 in Rimini with a presentation on “Analysis of “High‐risk” host cell proteins (HCPs)” More info at the...

Philochem to attend the 71st American Society for Mass Spectrometry Conference on June 4-8, 2023

by Lisa Nadal | May 12, 2023 | Past Events

Dr. Ettore Gilardoni (Head of Bio-MS) will present a poster entitled: Proteomic analysis reveals insights into the mechanism of the Intra-cork approach for increasing therapeutic window of immunocytokines Domenico Ravazza, (1st year PhD Student), will present a poster...

Philogen to attend AACR Annual Meeting in Orlando on April 14-18, 2023

by Lisa Nadal | Mar 16, 2023 | Past Events

Prof. Dr. Dario Neri (CEO and CSO), Dr. Covelli (CMO), Dr. Dakhel, Dr. De Luca, Dr. Cazzamalli, Dr. Galbiati, Dr. Puca, Sara Puglioli. Matilde Bocci, Giulia Rotta, Eleonora Prodi and Aureliano Zana will participate at the event. Moreover, the following abstracts have...

Philogen to attend Mid & Small | London 2023 Conference on April 20, 2023

by Lisa Nadal | Mar 16, 2023 | Past Events

Prof. Dario Neri (CEO and CSO), and Emanuele Puca (Investor Relations) will participate at the event to present Philogen and its programs to the financial community.

Philogen to attend 19th EADO Congress on April 20-22, 2023

by Lisa Nadal | Mar 16, 2023 | Past Events

Dr. Covelli (CMO), Dr. Elia, Dr. Ravenni, and Dr. Nadal will participate at the event in Rome. The dermato-oncology team from St. Gallen will give a presentation entitled “Intralesional administration of L19IL2/L19TNF in difficult-to-treat BCC patients shows favorable...

Philogen to attend the TIDES Europe 2022 in Vienna, Austria (16-18 November)

by last | Nov 13, 2022 | 2022, Past Events

Philogen will attend the TIDES Europe in Vienna in November 2022. Samuele Cazzamalli, Head of Small Molecules Therapeutics at Philogen, will give a lecture entitled “Non-internalizing Small Molecule-Drug Conjugates and Radioligand Therapeutics targeting Fibroblast...
« Older Entries
Next Entries »

Recent Posts

  • 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
  • Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025
  • Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties
  • Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
  • Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
Privacy Policy / Cookie Policy

Contacts

  • Follow

Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch